Device-based nerve stimulation for relapse-preventing kidney disease in kids
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a small non-surgical device can help keep children with steroid-sensitive nephrotic syndrome in remission. If it works, it could lower the chance of relapse (kidney flare-ups) and help maintain kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has steroid-sensitive nephrotic syndrome that goes into remission with steroids (often called FRNS)
- Your child is between ages 3 and 17
- Kidneys are functioning enough: eGFR is at least 30
- Diagnosis is minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS)
- At enrollment, your child is currently in remission (protein in urine is very low/negative for several days)
- Parent/guardian can consent, and your child can assent if age 7 or older
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This pilot study tests a device that stimulates nerves in the ear to help children with steroid-resistant nephrotic syndrome. It may improve urine protein and kidney-related outcomes for kids whose standard steroid treatment does not work.
This trial tests whether rituximab works as well as mycophenolate in children whose nephrotic syndrome (kidney condition) comes back when steroid medicines are reduced. It aims to find the safest and most effective option during a relapse.
This trial tests if a hormone called ACTH can help children with nephrotic syndrome who have frequent relapses or need steroids to stay in remission. It aims to find a treatment that may reduce the need for steroids and prevent relapses.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
Hear when a new Nephrotic Syndrome in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.